Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 12, 2010, Pages 1386-1394

  Coimbra, S ^a,b,c   Oliveira, H ^d   Reis, F ^e   Belo, L ^a,b   Rocha, S ^a,b   Quintanilha, A ^a,b   Figueiredo, A ^d   Teixeira, F ^e   Castro, E ^a,b   Rocha Pereira, P ^b,f   Santos Silva, A ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c CESPU   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

adipokines; body mass index; C reactive protein; psoriasis therapy; psoriasis vulgaris; severity

Indexed keywords

ADIPONECTIN; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; C REACTIVE PROTEIN; CALCITRIOL; INTERLEUKIN 6; LEPTIN; METHOXSALEN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PORTUGAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PSORIASIS VULGARIS; PUVA; ULTRAVIOLET B RADIATION;

ADIPOKINES; BODY MASS INDEX; FEMALE; HUMANS; MALE; PORTUGAL; PSORIASIS; PUVA THERAPY; SEVERITY OF ILLNESS INDEX;

EID: 78449267411     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03647.x     Document Type: Article

References (43)

1. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-39.
2. Vanizor Kural B, Orem A, Cimsit G, et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003; 328: 71-82.
3. Coimbra S, Oliveira H, Reis F, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci 2009; 55: 202-204.
4. Pietrzak A, Lecewicz-Torun B,. Activity of serum lipase [EC 3.1.1.3] and the diversity of serum lipid profile in psoriasis. Med Sci Monit 2002; 8: CR9 - CR13.
5. Uyanik BS, Ari Z, Onur E, et al. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002; 40: 65-68.
6. Piskin S, Gurkok F, Ekuklu G, et al. Serum lipid levels in psoriasis. Yonsei Med J 2003; 44: 24-26.
7. Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR, et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003; 48: 882-885.
8. Mallbris L, Granath F, Hamsten A, et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-621.
9. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004; 150: 917-928. (Pubitemid 38903524)
10. Chodorowska G, Juszkiewicz-Borowiec M, Czelej D, et al. Activity of tumor necrosis factor-alfa (TNF-alpha) and selected acute phase proteins in plasma of psoriatic patients receiving local treatment. Ann Univ Mariae Curie Sklodowska [Med] 2001; 56: 165-169.
11. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M,. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004; 18: 180-183.
12. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
13. Sterry W, Strober BE, Menter A,. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649-655.
14. Setty AR, Curhan G, Choi HK,. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses' Health Study II. Arch Intern Med 2007; 167: 1670-1675.
15. Clark L, Lebwohl M,. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008; 58: 443-446.
16. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
17. Wellen KE, Hotamisligil GS,. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788.
18. Panagiotakos DB, Pitsavos C, Yannakoulia M, et al. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 2005; 183: 308-315.
19. Calabro P, Yeh ET,. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep 2008; 10: 32-38.
20. Meier CA, Thalmann S,. [White adipose tissue, inflammation and atherosclerosis]. Bull Acad Natl Med 2007; 191: 897-908.
21. Takemura Y, Walsh K, Ouchi N,. Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep 2007; 9: 238-243.
22. Rondinone CM,. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006; 29: 81-90.
23. Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005: 273-279.
24. Tilg H, Moschen AR,. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008; 114: 275-288.
25. Aguilera CM, Gil-Campos M, Canete R, et al. Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome. Clin Sci (Lond) 2008; 114: 183-193.
26. Rothenbacher D, Brenner H, Marz W, et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005; 26: 1640-1646.
27. Owecki M, Miczke A, Pupek-Musialik D, et al. Serum adiponectin concentrations and their relationship with plasma lipids in obese diabetic and non-diabetic Caucasians. Neuro Endocrinol Lett 2007; 28: 901-907.
28. Lautamaki R, Ronnemaa T, Huupponen R, et al. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 2007; 56: 881-886.
29. Fantuzzi G,. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-919.
30. Shibata S, Saeki H, Tada Y, et al. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009; 55: 62-63.
31. Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008; 159: 1207-1208.
32. Takahashi H, Tsuji H, Takahashi I, et al. Prevalence of obesity/adiposity in Japanese psoriasis patients: adiposity is correlated with the severity of psoriasis. J Dermatol Sci 2009; 55: 74-76.
33. Kaur S, Zilmer K, Kairane C, et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008; 159: 1364-1367.
34. Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008; 159: 342-350.
35. Wang Y, Chen J, Zhao Y, et al. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008; 158: 1134-1135.
36. Utzschneider KM, Carr DB, Tong J, et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005; 48: 2330-2333.
37. Bokarewa M, Nagaev I, Dahlberg L, et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-5795.
38. Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144: 1571-1575.
39. Cerman AA, Bozkurt S, Sav A, et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008; 159: 820-826.
40. Frederiksson TPU,. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
41. Naldi L, Gambini D,. The clinical spectrum of psoriasis. Clin Dermatol 2007; 25: 510-518.
42. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
43. Sakai R, Matsui S, Fukushima M, et al. Prognostic factor analysis for plaque psoriasis. Dermatology 2005; 211: 103-106.